• Pediatric Gastroenterology, Hepatology & Nutrition
• /
• 제23권2호
• /
• pp.154-162
• /
• 2020

Purpose: The Cow's Milk-related Symptom Score (CoMiSS^TM), which considers crying, regurgitation, stools, skin and respiratory symptoms, was developed as an awareness tool for evaluating cow's milk-related symptoms. The scoring ranges from 0 to 33. A score ≥12 was proposed as being likely cow's milk-related and suggestive of allergy to cow's milk. This study aimed to determine the age-related CoMiSS^TM values in presumed healthy infants in Poland. Methods: This was a cross-sectional study conducted in well-child clinics in two locations. Parents of the presumed healthy infants aged ≤6 months were approached during a routine checkup/vaccination visit. The exclusion criteria were as follows: presence of acute or chronic diseases, preterm delivery, treatment with therapeutic formula, and use of any food supplements (except vitamins) or medications. Results: Data from 226 infants were obtained (median age [Q1-Q3], 4 months [3-4]). The overall median (Q1-Q3) and mean (standard deviation) CoMiSS^TM values were 4 (2-7) and 4.7 (3.5), respectively. The 95th percentile was 11. Scores on some, albeit not all, components of the CoMiSS^TM significantly differed between age groups (crying, stools) or feeding type groups (stools and skin symptoms). Eleven children (4.9%) scored ≥12. Conclusion: This study adds to earlier age-related CoMiSS^TM data by providing CoMiSS^TM values in presumed healthy infants in Poland.

• Preventive Nutrition and Food Science
• /
• 제16권3호
• /
• pp.248-252
• /
• 2011

Soy protein based formula (SPF) has been developed for infants who are at a high risk for atopic dermatitis (AD) and cow's milk protein allergy (CMA). We performed this study to evaluate the therapeutic efficacy and safety of SPF compared to conventional hydrolyzed cow's milk formula (hCMF) in the feeding of infants with AD and CMA. 38 infants (12 to 24 months of age) diagnosed with CMA and AD were randomized to receive either SPF or hCMF for 12 weeks. Follow-up was conducted at 4, 8 and 12 weeks. Growth parameters of the infants were evaluated during each visit. Clinical evaluations, including AD severity scores, pruritus, specific immunoglobulin E (IgE) (cow's milk protein and soy protein) levels of peripheral blood, were made at enrollment and week 12. Analysis was performed on the 32 infants (SPF: n=16, hCMF: n=16) who completed the 12-week intervention. Eczema area and severity index (EASI) scores, a measure of the severity of AD, and pruritus were significantly reduced after 12 weeks compared to enrollment in the both groups; however, the median changes for EASI scores and pruritus were not statistically different between the two groups. The growth parameters did not differ significantly between both groups at any assessed time point. This study suggests that SPF could be useful in decreasing the severity of AD without affecting infant growth status. Therefore SPF could provide an adequate and safe alternative to hCMF in treating infants with AD and CMA during the first 12 to 24 months of their life.

• Journal of Dairy Science and Biotechnology
• /
• 제24권2호
• /
• pp.1-9
• /
• 2006

Goat milk is digested better than cow milk, because the fat globules in goat milk are smaller and the protein is similar to human milk, and assimilated easily. Goat milk is particularly rich in taurine (4.7mg/100mL) and retinol (40mg/100mL). Therefore, it might be recommened to heal dyspepsia and infants allergy by cow milk. However, during winter, supply of goat milk products are unsteady in Korea, because unbalance of demand and supply is resulted from seasonal breeding. Dairy industry for goat milk will be able to grow much more, if goat milk products can keep steady supply without changing by season. This review includes the physicochemical characteristics of goat milk, domestic production of goat milk, domestic goat milk products and future development.

• Pediatric Gastroenterology, Hepatology & Nutrition
• /
• 제4권2호
• /
• pp.238-242
• /
• 2001

저자들은 우유 단백질에 대한 FPIES의 1례를 경험하였기에 문헌 고찰과 함께 보고하는 바이다.

• Pediatric Gastroenterology, Hepatology & Nutrition
• /
• 제17권2호
• /
• pp.61-73
• /
• 2014

Presented are guidelines for the prevention, diagnosis, and treatment of cow's milk protein allergy (CMPA) which is the most common food allergy in infants. It manifests through a variety of symptoms that place a burden on both the infant and their caregivers. The guidelines were formulated by evaluation of existing evidence-based guidelines, literature evidence and expert clinical experience. The guidelines set out practical recommendations and include algorithms for the prevention and treatment of CMPA. For infants at risk of allergy, appropriate prevention diets are suggested. Breastfeeding is the best method for prevention; however, a partially hydrolyzed formula should be used in infants unable to be breastfed. In infants with suspected CMPA, guidelines are presented for the appropriate diagnostic workup and subsequent appropriate elimination diet for treatment. Exclusive breastfeeding and maternal dietary allergen avoidance are the best treatment. In infants not exclusively breastfed, an extensively hydrolyzed formula should be used with amino acid formula recommended if the symptoms are life-threatening or do not resolve after extensively hydrolyzed formula. Adherence to these guidelines should assist healthcare practitioners in optimizing their approach to the management of CMPA and decrease the burden on infants and their caregivers.

• Pediatric Gastroenterology, Hepatology & Nutrition
• /
• 제4권1호
• /
• pp.47-53
• /
• 2001

목 적: 우유 과민성 장병증(cow's milk-sensitive enteropathy, CMSE)은 글루텐 과민성 장병증과는 달리 일시적인 질환으로 알려져 있다. CMSE의 장기 추적관찰을 통하여 우유 및 타 음식에 대한 내성 시기, 발현 증상, 알레르기 질환 동반 유무, 가족력 등을 파악하여 환자에 대한 예후설명, 수유방법의 변화시기와 이유식의 이용 등 향후 식이 조절에 대한 지침을 마련하고자 본 연구를 시행하였다. 대상 및 방법: 1992년 3월부터 1997년 3월까지 대구가톨릭대학병원 소아과에서 성장장애와 설사를 주소로 내원하여, 우유 유발 및 제거시험, 소장 생검조직의 형태학적 계측을 통하여 CMSE로 진단받은 후 추적 관찰과 전화 설문이 가능하였던 21명을 대상으로 하였다. 입원당시 연령은 $30.7{\pm}8.8$ (18~47)일, 설문당시는 $43.4{\pm}23.7$ (16~84)개월이였다. 생후 6개월까지는 절대적으로 단백가수 분해물을 수유하게 하였으며, 추후 2개월 간격으로 유발시험을 시행하는 치료 계획서를 작성 이용하였다. 결 과: 1) 우유를 먹여도 내성을 보였던 최종 연령은 $12.6{\pm}3.7$ (6~24)개월이었다. 2) 나이에 적합한 식이 가능한 모든 식품에 내성을 보였던 연령은 $15.5{\pm}3.7$ (10~24)개월이었다. 3) 우유 유발시험에 따라 관찰된 유해반응 19회 중 구토(31%), 설사(31%), 보챔 혹은 기면(21%), 발진(10%), 복부팽만(5%)의 증세를 보였다. 4) 입원당시 혈중 IgE와 우유 RAST에 양성을 보인 5명과 음성을 보였던 16명을 비교하여 우유 및 타 식품에 대한 내성 시기(p>0.05), 타 알레르기 질환의 발현 유무, 알레르기 가족력에서 의미 있는 차이가 관찰되지 않았다. 결 론: CMSE는 2세 이내에 임상적으로 완전한 회복을 보인다. 우유에 대하여 61%에서 1세까지, 전례에서 2세 전까지 내성을 보여 영유아기의 일시적 질환으로 판단된다. 타 식품에 대한 알레르기 발현은 특정 음식보다는 개인에 따른 다양한 음식물에서 발생하며, 전례에서 2세까지 내성을 보인다. 진단 당시 우유 RAST, 혈중 IgE의 상승과 우유 및 타 식품에 대한 내성의 발현 시기와는 무관하다.

• Clinical and Experimental Pediatrics
• /
• 제46권9호
• /
• pp.839-845
• /
• 2003

우유 알레르기는 영유아에서 흔하고 중요한 질환이다. 유병률은 1-3% 정도 되고 이를 진단하기 위해 자세한 문진을 시행하여야 한다. 피부반응검사 및 특이 IgE 검사로 도움을 받을 수 있으며 확진을 위해서는 경구유발검사가 필요하다. 실제 우유 알레르기 환자로 진단하였으면 치료 지침에 따라 대응하여야 한다.

• Pediatric Gastroenterology, Hepatology & Nutrition
• /
• 제24권4호
• /
• pp.384-391
• /
• 2021

Purpose: The Cow's Milk-related Symptom Score (CoMiSS^TM) was developed as an awareness tool for evaluating cow's milk-related symptoms in otherwise healthy children. Using a convenience sample of participants, this cross-sectional study aimed to determine CoMiSS^TM values of symptomatic infants based on retrospectively or prospectively obtained information. Methods: CoMiSS^TM values were determined in infants aged <12 months with symptoms suggestive of cow's milk protein allergy or functional gastrointestinal disorders. The exclusion criteria were previous diagnosis with acute or chronic disease, treatment with a therapeutic formula, and in case of breastfeeding, an elimination diet followed by the mother. Two CoMiSS^TM values were assessed. A retrospective collection was defined as the collection of data after initial contact with the medical center but before the first medical consultation. A prospective collection was defined as the collection of data within 24 hours from the time of medical consultation but before starting any therapeutic intervention. The CoMiSS^TM total and individual component scores obtained retrospectively or prospectively were compared between groups using the Wilcoxon signed-rank test. Results: This study was performed between August and November 2019. Data of 110 children (62 males and 48 females), with a mean±standard deviation age of 18.2±11.7 weeks, were obtained. The total CoMiSS^TM value (p<0.001) and some individual component scores (crying, regurgitation, and stool) were significantly lower when collected prospectively than when collected retrospectively. Conclusion: CoMiSS^TM values were retrospectively and prospectively determined. Lower CoMiSS^TM values were obtained during prospective evaluation. Possible differences should be considered when using CoMiSS^TM in clinical practice.

• Pediatric Gastroenterology, Hepatology & Nutrition
• /
• 제26권5호
• /
• pp.277-283
• /
• 2023

Purpose: Cow's milk protein allergy (CMPA) is a common condition in infants, but little is known about healthcare providers' clinical experience treating infants with CMPA. To address this gap, we analyzed prospectively collected data from healthcare providers (HCPs) who treated infants under six months old with suspected CMPA using hypoallergenic formulas. The study focused on a commercial extensively hydrolyzed formula containing Lactobacillus rhamnosus GG (ATCC53103) (eHF-LGG) or a commercial amino acid formula (AAF). Methods: In this secondary analysis of prospectively collected survey data, 52 HCPs treated 329 infants under six months old with suspected CMPA using hypoallergenic formulas. A series of two de-identified surveys per patient were collected by HCPs to assess short-term symptom relief in the patients and HCP's satisfaction with the management strategies. The initial survey was completed at the initiation of treatment of CMPA, and the second survey was completed at a follow-up visit. Results: The majority of HCPs (87%) in the study were general pediatricians, and most saw 2 to 10 CMPA patients weekly. Results showed that clinicians reported satisfaction with treatment in 95% of patients in the EHF cohort and 97% of patients in the AAF cohort and achieved expected clinical results in 93% and 97% of patients using eHF and AAF, respectively. Furthermore, few patients were switched from the hypoallergenic formula once initiated. Conclusion: The study provides new insights into HCP perspectives on treating infants with CMPA and supports using hypoallergenic formulas to manage this condition. However, additional prospective controlled studies are needed to confirm these initial findings.

• Neonatal Medicine
• /
• 제15권1호
• /
• pp.75-79
• /
• 2008

목 적 : 혈변을 보였으나 확진 할 수 없었던 4개월 이하의 영아에서 내원 당시의 임상 상태 및 2년 후의 추적관찰을 통해 얻은 정보로 임상 소견 및 향후 알레르기 질환의 발현 여부에 대하여 알아보고 치료 방침 설정에 도움이 되고자 본 연구를 시행하였다. 방 법 : 신생아와 조기 영아기에 혈변을 보았던 환아들 중 감염 및 수술적 질환을 제외한 환아의 임상소견 및 2년 후의 추적관찰을 시행하였다. 결 과 : 모든 환아에서 RAST 우유 검사는 음성이었고, 환아들 모두는 자연 호전 되었으며, 2년 후 추적관찰 결과 예후는 양호하였다. 내원 당시의 총 호산구수 증가 유무에 따른 2년 후의 알레르기 성향에서 차이를 보이지 않았다. 결 론 : 신생아와 조기 영아기에 혈변을 보았던 환아들 중 감염 및 수술적 질환을 제외한 환아의 임상양상 및 예후는 모두 양호하였고, 특별한 치료 없이 모두 호전되었으므로 불필요한 치료를 배제할 수 있을 것이다.